Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.
2.

Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.

Hainsworth JD, Meluch AA, Litchy S, Schnell FM, Bearden JD, Yost K, Greco FA.

Cancer. 2005 Jun 1;103(11):2298-303.

3.

Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function.

Morales-Barrera R, Bellmunt J, Suárez C, Valverde C, Guix M, Serrano C, Gallén M, Carles J.

Eur J Cancer. 2012 Aug;48(12):1816-21. doi: 10.1016/j.ejca.2012.04.002. Epub 2012 May 16.

PMID:
22595043
4.

Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.

Hainsworth JD, Burris HA 3rd, Erland JB, Morrissey LH, Meluch AA, Kalman LA, Hon JK, Scullin DC Jr, Smith SW, Greco FA.

Cancer. 1999 Mar 15;85(6):1269-76.

PMID:
10189131
5.

Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.

Kanai K, Kikuchi E, Ohigashi T, Miyajima A, Nakagawa K, Nakashima J, Oya M.

Int J Clin Oncol. 2008 Dec;13(6):510-4. doi: 10.1007/s10147-008-0779-x. Epub 2008 Dec 18.

PMID:
19093178
6.

Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.

Shelley M, Cleves A, Wilt TJ, Mason M.

Cochrane Database Syst Rev. 2011 Apr 13;(4):CD008976. doi: 10.1002/14651858.CD008976.pub2. Review.

PMID:
21491413
7.

Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.

Calabrò F, Lorusso V, Rosati G, Manzione L, Frassineti L, Sava T, Di Paula ED, Alonso S, Sternberg CN.

Cancer. 2009 Jun 15;115(12):2652-9. doi: 10.1002/cncr.24313.

8.

The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group.

Bamias A, Moulopoulos LA, Koutras A, Aravantinos G, Fountzilas G, Pectasides D, Kastritis E, Gika D, Skarlos D, Linardou H, Kalofonos HP, Dimopoulos MA.

Cancer. 2006 Jan 15;106(2):297-303.

9.

A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.

Grivas PD, Hussain M, Hafez K, Daignault-Newton S, Wood D, Lee CT, Weizer A, Montie JE, Hollenbeck B, Montgomery JS, Alva A, Smith DC.

Urology. 2013 Jul;82(1):111-7. doi: 10.1016/j.urology.2013.03.044. Epub 2013 May 21.

PMID:
23706253
10.

Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.

Ikeda M, Matsumoto K, Tabata K, Minamida S, Fujita T, Satoh T, Iwamura M, Baba S.

Jpn J Clin Oncol. 2011 Oct;41(10):1214-20. doi: 10.1093/jjco/hyr131. Epub 2011 Sep 8.

PMID:
21903707
11.
12.

Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma.

Matsumoto K, Irie A, Satoh T, Okazaki M, Iwamura M, Baba S.

Int J Urol. 2007 Nov;14(11):1000-4; discussion 1004.

13.

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.

Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, Chatta GS, Nanus DM, Glode LM, Trump DL, Chen H, Smith DC; National Cancer Institute.

J Clin Oncol. 2007 Jun 1;25(16):2218-24. Erratum in: J Clin Oncol. 2008 Jul 1;26(19): 3295.

PMID:
17538166
14.

Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.

Li J, Juliar B, Yiannoutsos C, Ansari R, Fox E, Fisch MJ, Einhorn LH, Sweeney CJ.

J Clin Oncol. 2005 Feb 20;23(6):1185-91.

PMID:
15718315
16.

Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.

Iwasaki K, Obara W, Kato Y, Takata R, Tanji S, Fujioka T.

Jpn J Clin Oncol. 2013 Feb;43(2):193-9. doi: 10.1093/jjco/hys213. Epub 2012 Dec 28.

PMID:
23275643
17.

Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.

Kaya AO, Coskun U, Ozkan M, Sevinc A, Yilmaz AU, Gumus M, Unal OU, Ozdemir NY, Alici S, Berk V, Degerli H, Oner MK, Ozturk C, Kefeli U, Camcı C; Anatolian Society of Medical Oncology (ASMO).

Onkologie. 2012;35(10):576-80. doi: 10.1159/000342674. Epub 2012 Sep 18.

PMID:
23038228
18.

Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens.

Ricci S, Galli L, Chioni A, Iannopollo M, Antonuzzo A, Francesca F, Vocaturo V, Selli C, Orlandini C, Conte P.

Cancer. 2002 Oct 1;95(7):1444-50.

19.

Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning.

Hensley ML, Correa DD, Thaler H, Wilton A, Venkatraman E, Sabbatini P, Chi DS, Dupont J, Spriggs D, Aghajanian C.

Gynecol Oncol. 2006 Aug;102(2):270-7. Epub 2006 Feb 20.

PMID:
16490239
20.

Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy.

Nogué-Aliguer M, Carles J, Arrivi A, Juan O, Alonso L, Font A, Mellado B, Garrido P, Sáenz A; Spanish Cooperative Group.

Cancer. 2003 May 1;97(9):2180-6.

Supplemental Content

Support Center